Evidence map›Paper›PMID 28396402›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

APC/C

Verónica Bobo-Jiménez, María Delgado-Esteban, Julie Angibaud, Irene Sánchez-Morán, Antonio de la Fuente, Javier Yajeya, U Valentin Nägerl, José Castillo, Juan P Bolaños, Angeles Almeida

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Verónica Bobo-JiménezInstitute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, Consejo Superior de Investigaciones Científicas, 37007 Salamanca, Spain.
María Delgado-EstebanInstitute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, Consejo Superior de Investigaciones Científicas, 37007 Salamanca, Spain.
Julie AngibaudInterdisciplinary Institute for Neuroscience, University of Bordeaux, CNRS UMR 5297, 33077 Bordeaux, France.
Irene Sánchez-MoránInstitute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, Consejo Superior de Investigaciones Científicas, 37007 Salamanca, Spain.
Antonio de la FuenteDepartment of Physiology and Pharmacology, Faculty of Medicine, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain.
Javier YajeyaDepartment of Physiology and Pharmacology, Faculty of Medicine, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain.
U Valentin NägerlInterdisciplinary Institute for Neuroscience, University of Bordeaux, CNRS UMR 5297, 33077 Bordeaux, France.
José CastilloClinical Neurosciences Research Laboratory, Department of Neurology, University Hospital, Health Research Institute of Santiago de Compostela, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
Juan P BolañosInstitute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, Consejo Superior de Investigaciones Científicas, 37007 Salamanca, Spain.
Angeles AlmeidaInstitute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, Consejo Superior de Investigaciones Científicas, 37007 Salamanca, Spain; aaparra@usal.es.ORCID 0000-0003-0485-8904
Universidad de Salamanca · ESCentre National de la Recherche Scientifique · FRUniversidade de Santiago de Compostela · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disruption of neuronal morphology contributes to the pathology of neurodegenerative disorders such as Alzheimer's disease (AD). However, the underlying molecular mechanisms are unknown. Here, we show that postnatal deletion of Cdh1, a cofactor of the anaphase-promoting complex/cyclosome (APC/C) ubiquitin ligase in neurons [Cdh1 conditional knockout (cKO)], disrupts dendrite arborization and causes dendritic spine and synapse loss in the cortex and hippocampus, concomitant with memory impairment and neurodegeneration, in adult mice. We found that the dendrite destabilizer Rho protein kinase 2 (Rock2), which accumulates in the brain of AD patients, is an APC/C

Indexed as

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnaphase-Promoting Complex-CyclosomeAnimalsCdh1 ProteinsCell SurvivalDendritic CellsGene Expression RegulationMemoryMiceMice, KnockoutNeuronsProtein Kinase Inhibitorsrho-Associated KinasesSignal Transduction1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnaphase-Promoting Complex-CyclosomeCdh1 ProteinsfasudilFzr1 protein, mouseProtein Kinase Inhibitorsrho-Associated KinasesRock2 protein, mouseAPC/CCdh1dendritememoryneurodegenerationRock

Identifiers

PMID28396402
PMCPMC5410848
OpenAlexW2606398649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.